The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to Lifestyle Intervention in Obesity
Open accessAbstract
OBJECTIVE—To assess long-term weight loss efficacy and safety of pramlintide used at different dosing regimens and in conjunction with lifestyle intervention (LSI). RESEARCH DESIGN AND METHODS—In a 4-month, double-blind, placebo-controlled, dose-ranging study, 411 obese subjects were randomized to receive pramlintide (six arms: 120, 240, and 360 μg b.i.d. and t.i.d.) or placebo in conjunction with a structured LSI program geared toward weight loss. Of the 4-month evaluable subjects (n = 270), 77% opted to continue preexisting treatment during an 8-month single-blind extension (LSI geared toward weight maintenance). RESULTS—At month 4, mean weight loss from baseline in the pramlintide arms ranged from 3.8 ± 0.7 to 6.1 ± 0.8 kg (2.8 ± 0.8 kg with placebo). By month 12, initial 4-month weight loss was regained in the placebo group but was maintained in all but the 120-μg b.i.d. group. Placebo-corrected weight loss with 120 μg t.i.d. and 360 μg b.i.d. averaged 3.2 ± 1.2 kg (3.1 ± 1.1% body wt) and 3.3 ± 1.1 kg (3.1 ± 1.0% body wt), respectively, at month 4 (both P < 0.01; 4-month evaluable n = 270) and 6.1 ± 2.1 kg (5.6 ± 2.1% body wt) and 7.2 ± 2.3 kg (6.8 ± 2.3% body wt), respectively, at month 12 (both P < 0.01; 12-month evaluable n = 146). At month 12, 40 and 43% of subjects treated with 120 μg t.i.d. and 360 μg b.i.d., respectively, achieved ≥10% weight loss (vs. 12% for placebo). Nausea, the most common adverse event with pramlintide in the 4-month study (9–29% pramlintide vs. 2% placebo), was generally mild to moderate and occurred in <10% of subjects during the extension. CONCLUSIONS—When used over 12 months as an adjunct to LSI, pramlintide treatment, with low-dose three-times-daily or higher-dose two-times-daily regimens, helped obese subjects achieve greater initial weight loss and enhanced long-term maintenance of weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Pramlintide is the first synthetic amylin analogue that approved for diabetes management with WL up to 7.9% [86].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [86]
Experimental — accuracy not yet measuredIn the citing paper
“Furthermore, the pramlintide 120 lg three times daily group demonstrated a significant placebocorrected 4.6-mm Hg reduction in SBP and a trend toward improvement with a placebo-corrected 2.6-mm Hg decrease in DBP.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [215]
In the citing paper
“In one study, 215 placebo-corrected weight loss at month 12 for the pramlintide 120 lg three times daily group averaged 6.1 kg, with higher doses providing little additional benefit.”
From Obesity‐Related Hypertension: Pathogenesis, Cardiovascular Risk, and Treatment: A Position Paper of The Obesity Society and the American Society of Hypertension (2013) · cites this paper as [215]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2000) · PubMed · Cited by 13,173
Randomized Trial of Lifestyle Modification and Pharmacotherapy for Obesity
Wadden, T. A., Berkowitz, R. I., Womble, L. G., Sarwer, D. B., Phelan, S., Cato, R. K., Hesson, L. A., Osei, S. Y., Kaplan, R., & Stunkard, A. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050156 · Cited by 794 · cited 2×
“Although the aforementioned factors, and differences in study designs, make it difficult to contextualize pramlintide’s long-term efficacy, it is noteworthy that the proportion of subjects achieving 5 and 10% weight loss at 1 year compares quite favorably to the results reported with oral weight loss medications (15,1…”
BackgroundResultRoth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436 · cited 1×
“In diet-induced obese rats, amylin induced synergistic, fat-specific weight loss when coadministered with leptin, a long-term adiposity signal (22).”
BackgroundSelf-citationHollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · cited 1×
“This is consistent with findings from 1-year pramlintide diabetes studies, which also showed durable weight loss over 1 year (12,16,17).”
Self-citationRatner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307 · cited 1×
“This is consistent with findings from 1-year pramlintide diabetes studies, which also showed durable weight loss over 1 year (12,16,17).”
Self-citationEffect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1732-4 · Cited by 205
Self-citationAronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2003 · Cited by 178 · cited 1×
“vious studies (9), pramlintide-mediated weight loss was clearly dissociable from the occurrence of nausea.”
BackgroundSelf-citationRoth, J. D., Hughes, H., Kendall, E., Baron, A. D., & Anderson, C. M. (2006) · Endocrinology · doi:10.1210/en.2006-0393 · Cited by 171
Anorectics on Trial: A Half Century of Federal Regulation of Prescription Appetite Suppressants
Colman, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-143-5-200509060-00013 · Cited by 167 · cited 2×
“To date, efforts to develop obesity pharmacotherapies aimed at reducing food intake and body weight have largely focused on smallmolecule anorectics, an approach that has repeatedly been hampered by safety concerns (1).”
BackgroundSmith, I. G., & Goulder, M. A. (2001) · PubMed · Cited by 149
Research works printed but not linked: 1
- National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report [article online], 1998 (NIH publ. no. 98-4083). Available from http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/obesity/obesity.pdf. Accessed 8 December 2005
Cited by
Landsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · The Journal of Clinical Hypertension · doi:10.1111/jch.12049 · Cited by 528
Self-citationAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
“Pramlintide was evaluated in conjunction with lifestyle intervention in a phase 2b dose-ranging proof-of-concept study (Smith et al., 2008).”
BackgroundMethodInfluentialRavussin, E., Smith, S. R., Mitchell, J. A., Shringarpure, R., Shan, K., Maier, H., Koda, J. E., & Weyer, C. (2009) · Obesity · doi:10.1038/oby.2009.184 · Cited by 332
Self-citationWhat is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Pramlintide is the fi rst synthetic amylin analogue that approved for diabetes management with WL up to 7.9% [86].”
InfluentialLandsberg, L., Aronne, L. J., Beilin, L. J., Burke, V., Igel, L. I., Lloyd‐Jones, D., & Sowers, J. (2013) · Obesity · doi:10.1002/oby.20181 · Cited by 284
Self-citationLau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01751-7 · Cited by 278
Pharmacotherapies for Obesity: Past, Current, and Future Therapies
Ioannides-Demos, L. L., Piccenna, L., & McNeil, J. J. (2011) · Journal of Obesity · doi:10.1155/2011/179674 · Cited by 243
“pramlintide 120 μg twice daily arm [108].”
Body Weight Considerations in the Management of Type 2 Diabetes
Apovian, C. M., Okemah, J., & O’Neil, P. M. (2019) · Advances in Therapy · doi:10.1007/s12325-018-0824-8 · Cited by 239
Emerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Contreras, C., Gonzalez, F., Fernø, J., Diéguez, C., Rahmouni, K., Nogueiras, R., & López, M. (2015) · Annals of Medicine · doi:10.3109/07853890.2014.919727 · Cited by 158
Boyle, C. N., Lutz, T. A., & Le Foll, C. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2017.11.009 · Cited by 142
Control of energy homeostasis by amylin
Lutz, T. A. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0905-1 · Cited by 139
Peptides And Peptide Conjugates: Therapeutics On The Upward Path
Ahrens, V. M., Bellmann‐Sickert, K., & Beck‐Sickinger, A. G. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.76 · Cited by 154
Adler, B. L., Yarchoan, M. M., Hwang, H. M., Louneva, N., Blair, J. A., Palm, R. F., Smith, M. A., Lee, H., Arnold, S. E., & Casadesús, G. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.10.076 · Cited by 140
“To this end, the synthetic amylin analog pramlintide causes clinical weight loss and is an approved adjunct to insulin to improve glycemic control in diabetic patients (Hollander et al., 2003; Smith et al., 2008).”
Management of antipsychotic-related weight gain
Maayan, L. A., & Correll, C. U. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.85 · Cited by 142
GLP-1 and Amylin in the Treatment of Obesity
Jorsal, T., Rungby, J., Knop, F. K., & Vilsbøll, T. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0693-3 · Cited by 125
Mack, C. M., Soares, C. J., Wilson, J., Athanacio, J., Turek, V. F., Trevaskis, J. L., Roth, J. D., Smith, P. A., Gedulin, B. R., Jodka, C. M., et al. (2009) · International Journal of Obesity · doi:10.1038/ijo.2009.238 · Cited by 118
Aronne, L. J., Halseth, A. E., Burns, C. M., Miller, S., & Shen, L. Z. (2010) · Obesity · doi:10.1038/oby.2009.478 · Cited by 102
Self-citationPramlintide and the treatment of diabetes: a review of the data since its introduction
Younk, L. M., Mikeladze, M., & Davis, S. N. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.581663 · Cited by 111
Burcelin, R., & Gourdy, P. (2016) · Obesity Reviews · doi:10.1111/obr.12465 · Cited by 105
“Amylin is too unstable to be used clinically; however, a synthetic version (pramlintide) is already approved for use in diabetes and is being examined in clinical trials for use as an anti-obesity therapy in individuals without diabetes (20).”
BackgroundEmerging glucagon-like peptide 1 receptor agonists for the treatment of obesity
Jepsen, M. M., & Christensen, M. B. (2021) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2021.1947240 · Cited by 96
Role of Amylin in Type 1 and Type 2 Diabetes
Hieronymus, L. B., & Griffin, S. (2015) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721715607642 · Cited by 95
Finan, B., Clemmensen, C., & Müller, T. D. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.07.003 · Cited by 88
Pharmacotherapy for childhood obesity: present and future prospects
Sherafat‐Kazemzadeh, R., Yanovski, S. Z., & Yanovski, J. A. (2012) · International Journal of Obesity · doi:10.1038/ijo.2012.144 · Cited by 93
Molecular Signature for Receptor Engagement in the Metabolic Peptide Hormone Amylin
Bower, R. L., Yule, L. R., Rees, T. A., Deganutti, G., Hendrikse, E. R., Harris, P. W. R., Kowalczyk, R., Ridgway, Z. M., Wong, A. G., Swierkula, K., et al. (2018) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.8b00002 · Cited by 80
Roth, J. D., Coffey, T. S., Jodka, C. M., Maier, H., Athanacio, J., Mack, C. M., Weyer, C., & Parkes, D. G. (2007) · Endocrinology · doi:10.1210/en.2007-0898 · Cited by 79
Self-citationSingh‐Franco, D., Pérez, A., & Harrington, C. A. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01337.x · Cited by 75
“…2.67 [1.56, 4.58] p = 0.0004 41% p = 0.18 PRA > 120 mcg/dose 3 131/512 39/262 1.84 [0.95, 3.54] p = 0.07 62% p = 0.07 #events/N, number of events per sample; PCB, placebo injection given at meal-time; PRA, pramlintide injection given at meal-time. from the Smith et al. 2008 study [8] are analysed.”
BackgroundMethodInfluentialPresent and Future: Pharmacologic Treatment of Obesity
Glandt, M., & Raz, I. (2011) · Journal of Obesity · doi:10.1155/2011/636181 · Cited by 95
“A more comprehensive study assessing the long-term weight loss efficacy and safety of pramlintide at different dosing regimens was carried out in 411 obese subjects [78].”
Pharmacological management of binge eating disorder: current and emerging treatment options
McElroy, S., Guerdjikova, A. I., Mori, N., & O’Melia, A. (2012) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s25574 · Cited by 74
“Affected peptides involved in controlling feeding and body weight include neuropeptide Y (eg, by topiramate and zonisamide), amylin (by pramlintide), and glucagon-like peptide-1 (by exenatide and liraglutide).(44,52,59,60) Growing research suggests medications with anorectic or weight loss effects may be helpful for p…”
Kennett, G. A., & Clifton, P. G. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.020 · Cited by 82
Pharmacologic Therapies for Obesity
Kaplan, L. M. (2010) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2010.01.001 · Cited by 76
Dahl, K., Toubro, S., Dey, S., Duque do Vale, R., Flint, A., Gasiorek, A., Heydorn, A., Jastreboff, A. M., Key, C., Petersen, S. B., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01185-7 · Cited by 80
Amylin as a Future Obesity Treatment
Dehestani, B., Stratford, N. R., & Roux, C. W. L. (2021) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes21071 · Cited by 72
“Significant loss in body weight vs. placebo Smith et al. (2008)12 16 Double-blind, placebo controlled 120 µg pramlintide bid 240 µg pramlintide bid 360 µg pramlintide bid 120 µg pramlintide tid 240 µg pramlintide tid 360 µg pramlintide tid Placebo 38 38 32 45 49 42 36 37.5± 5.0 37.7± 5.1 38.1± 5.4…”
MethodInfluentialAmylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
Mathiesen, D. S., Lund, A., Vilsbøll, T., Knop, F. K., & Bagger, J. I. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.617400 · Cited by 86
“To evaluate the sustainability of these results, a 12-month randomised, double-blinded, placebocontrolledmulticentre trial with 146 obese subjects (average BMI ~ 37 kg/m(2)) evaluated the effect of pramlintide combined with lifestyle intervention on long-term body weight loss (96).”
MethodBrain imaging studies of appetite in the context of obesity and the menstrual cycle
Vugt, D. A. V. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp051 · Cited by 82
“Pramlintide therapy (compared with placebo) together with life style modification produced significant and sustained weight loss (Smith et al., 2008).”
BackgroundObesity treatment: novel peripheral targets
Field, B. C. T., Chaudhri, O. B., & Bloom, S. R. (2009) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2009.03522.x · Cited by 73
What is the prognosis for new centrally-acting anti-obesity drugs?
Heal, D. J., Gosden, J., & Smith, S. L. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.017 · Cited by 70
“In a 4-month, Phase 2B trial in nondiabetic, obese subjects that also included a single-blind 8 month extension period, twice daily dosing of pramlintide (240 mg) was found to be as efficacious as the three times daily regime (Smith et al., 2008).”
Self-citationAmylin-mediated control of glycemia, energy balance, and cognition
Mietlicki‐Baase, E. G. (2016) · Physiology & Behavior · doi:10.1016/j.physbeh.2016.02.034 · Cited by 68
“The use of pramlintide, or any amylin analog, to treat obesity in humans would require chronic administration; accordingly, several studies have focused on the energy balance effects of longer-term pramlintide treatment in obese humans [157, 159-161].”
Trevaskis, J. L., Sun, C., Athanacio, J., D’Souza, L. J., Samant, M. P., Tatarkiewicz, K., Griffin, P. S., Wittmer, C., Wang, Y., Teng, C. ‐., et al. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12390 · Cited by 61
“GLP-1R [5] and amylin receptor agonists [6] induce a durable reduction in food intake”
BackgroundThe interaction of amylin with other hormones in the control of eating
Lutz, T. A. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01670.x · Cited by 63
Gastric Sensory and Motor Functions and Energy Intake in Health and Obesity—Therapeutic Implications
Cifuentes, L., Camilleri, M., & Acosta, A. J. (2021) · Nutrients · doi:10.3390/nu13041158 · Cited by 64
Adjunct therapy for type 1 diabetes mellitus
Lebovitz, H. E. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.49 · Cited by 59
“The effect of pramlintide in decreasing food intake is so potent that its use in the treatment of obesity is being tested in clinical trials”
Roth, J. D., Maier, H., Chen, S., & Roland, B. L. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.581 · Cited by 58
Leibel, R. L., Seeley, R. J., Darsow, T., Berg, E. G., Smith, S. R., & Ratner, R. (2015) · Diabetes · doi:10.2337/db15-0004 · Cited by 52
“Pramlintide, an amylin analog that is currently approved for the treatment of diabetes, also reduces food intake in obese subjects (93), and in studies examining its efficacy for weight reduction, pramlintide led to sustained weight loss over a year (94).”
BackgroundSelf-citationMack, C. M., Smith, P. A., Athanacio, J., Xu, K., Wilson, J., Reynolds, J. M., Jodka, C. M., Lu, M. G. W., & Parkes, D. G. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01465.x · Cited by 51
“Pramlintide reduced 24-h food intake [22] and meal size after a single meal [23], while sustained decreases in body weight were observed with and without lifestyle intervention in obese subjects [24,25].”
BackgroundThe Role of Pramlintide for Weight Loss
Dunican, K. C., Adams, N. M., & Desilets, A. R. (2010) · Annals of Pharmacotherapy · doi:10.1345/aph.1m210 · Cited by 51
Obesity Pharmacotherapy in Patients With Type 2 Diabetes
Kahan, S. I., & Fujioka, K. (2017) · Diabetes Spectrum · doi:10.2337/ds17-0044 · Cited by 58
“0 kg with higher doses of pramlintide (49,50).”
BackgroundCombined Amylin/GLP-1 pharmacotherapy to promote and sustain long-lasting weight loss
Liberini, C. G., Koch‐Laskowski, K., Shaulson, E. D., McGrath, L. E., Lipsky, R. K., Lhamo, R., Ghidewon, M. Y., Ling, T., Stein, L. M., & Hayes, M. R. (2019) · Scientific Reports · doi:10.1038/s41598-019-44591-8 · Cited by 54
Gut Peptides: Targets for Antiobesity Drug Development?
Moran, T. H., & Dailey, M. J. (2009) · Endocrinology · doi:10.1210/en.2009-0003 · Cited by 59
“Both peripheral and central sites of action for PYY(3-36) for inhibiting food intake have been proposed.”
BackgroundInfluentialPharmacologic Treatment of Obesity in Reproductive Aged Women
Nuako, A. A., Tu, L., Reyes, K. J. C., Chhabria, S. M., & Stanford, F. C. (2023) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-023-00350-1 · Cited by 67
Brainstem sensing of meal-related signals in energy homeostasis
Young, A. A. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.03.019 · Cited by 57
“loss (43% having lost >10% of body weight at 1 year) (Smith et al., 2008).”
BackgroundPharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 67
Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights
Geisler, C. E., & Hayes, M. R. (2023) · Physiology & Behavior · doi:10.1016/j.physbeh.2023.114236 · Cited by 53
Chan, J. L., Roth, J. D., & Weyer, C. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181b91911 · Cited by 47
“1% in subjects receiving placebo.(46) These findings in obese humans are consistent with nonclinical findings and provide validation for the DIO rodent as a relevant model for translational clinical research.”
ResultSelf-citationRoth, J. D., Trevaskis, J. L., Wilson, J., Lei, C., Athanacio, J., Mack, C. M., Kesty, N. C., Coffey, T. S., Weyer, C., & Parkes, D. G. (2008) · International Journal of Obesity · doi:10.1038/ijo.2008.91 · Cited by 43
Self-citationDo we need anti‐obesity drugs?
Hainer, V., & Hainerová, I. A. (2012) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2349 · Cited by 51
“patients without type 2 diabetes revealed weight loss of up to 8 kg after 1 year [80,81].”
BackgroundHay, D. L. (2017) · Headache The Journal of Head and Face Pain · doi:10.1111/head.13077 · Cited by 43
“Several human clinical studies of pramlintide as a weight loss treatment in obesity have been conducted but it is unclear whether any form of pramlintide is in development for this indication.(2,37,42) Other amylin agonists are being investigated.”
Trevaskis, J. L., Mack, C. M., Sun, C., Soares, C. J., D’Souza, L. J., Levy, O. E., Lewis, D. Y., Jodka, C. M., Tatarkiewicz, K., Gedulin, B. R., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078154 · Cited by 41
“Clinical trial data have shown that, similar to exenatide treatment, pramlintide therapy is associated with modest weight loss [17].”
BackgroundWeight Considerations in Pharmacotherapy for Type 2 Diabetes
Cheng, V., & Kashyap, S. R. (2010) · Journal of Obesity · doi:10.1155/2011/984245 · Cited by 46
“The efficacy of pramlintide was evaluated in obese, nondiabetic subjects in a double-blind, placebo-controlled doseranging study [32].”
BackgroundLarsen, A. T., Mohamed, K. E., Sonne, N., BREDTOFT, E.-M., Andersen, F., Karsdal, M. A., & Henriksen, K. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113842 · Cited by 43
Combination Drugs for Treating Obesity
Greenway, F. L., & Bray, G. A. (2010) · Current Diabetes Reports · doi:10.1007/s11892-010-0096-4 · Cited by 41
Combinations of drugs in the Treatment of Obesity
Halpern, B., Oliveira, E. S. L., Faria, A. M., Halpern, A., de Melo, M. E., Cercato, C., & Mancini, M. C. (2010) · Pharmaceuticals · doi:10.3390/ph3082398 · Cited by 43
“In previous studies with obese patients on monotherapy, this hormone showed maintained and prolonged weight loss [49].”
BackgroundAmylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
Walker, C. S., Aitken, J. F., Amarsingh, G. V., Zhang, S., & Cooper, G. J. S. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01125-9 · Cited by 40
“An amylin analogue, pramlintide, was registered by the FDA in 2005, for the treatment indications of type 1 diabetes mellitus (T1DM) and T2DM, and has shown anti-obesity activity in non-clinical models and clinical studies 6,7 .”
“Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations
Roth, J. D., Trevaskis, J. L., Turek, V. F., & Parkes, D. G. (2010) · Brain Research · doi:10.1016/j.brainres.2010.01.027 · Cited by 37
“…(Gantz et al., 2007; Heymsfield et al., 1999; Hukshorn et al., 2000; Jordan et al., 2008)), or only modest, single digit weight loss efficacy (in the case of amylin agonism (Aronne et al., 2007; Hollander et al., 2004; Smith et al., 2007, 2008)) in longer-term clinical studies of obese subjects.”
BackgroundGydesen, S., Andreassen, K. V., Hjuler, S. T., Hellgren, L. I., Karsdal, M. A., & Henriksen, K. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00419.2016 · Cited by 36
“Amylin receptor agonists (pramlintide and davalintide) have shown promise for weight reduction in preclinical models (19) and clinical settings (3, 26), and in combination with leptin (22) and small-molecule weight loss agents (4).”
BackgroundLarsen, A. T., Sonne, N., Andreassen, K. V., Gehring, K., Karsdal, M. A., & Henriksen, K. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.257576 · Cited by 34
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Son, J. W., le Roux, C. W., Blüher, M., Nauck, M. A., & Lim, S. (2026) · Endocrine Reviews · doi:10.1210/endrev/bnaf036 · Cited by 40
Larsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00678-2 · Cited by 33
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
“[79] reported results from a double-bl ind study of lifestyle combined with increasing doses of pramlintide or placebo.”
BackgroundLarsen, A. T., Sonne, N., Andreassen, K. V., Karsdal, M. A., & Henriksen, K. (2020) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.263392 · Cited by 35
“Pramlintide works by reducing postprandial blood glucose excursions and appetite, thereby leading to improved glucose control as well as a weight loss (Aronne et al., 2007; Ryan et al., 2008; Smith et al., 2008; Singh-Franco et al., 2011; Traina and Kane, 2011; Herrmann et al., 2014).”
BackgroundResultTreating the Chronic Disease of Obesity
Gossmann, M., Butsch, W. S., & Jastreboff, A. M. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.005 · Cited by 33
Pharmacological Treatment of Obesity
Kabra, D. G., Kabra, U. D., Tschöp, M. H., & Hofmann, S. M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3492-4_14 · Cited by 33
“Pramlintide treatment achieved greater weight loss and enhanced long-term maintenance of weight loss, when used over 12 months as an adjunct to lifestyle intervention in obese subject [ 143 ] .”
BackgroundEmerging drugs for the treatment of obesity
Martinussen, C., Bojsen-Møller, K. N., Svane, M. S., Dejgaard, T. F., & Madsbad, S. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1269744 · Cited by 28
“in the United States, demonstrating sustained weight loss over a year [89].”
BackgroundNo Guts, No Loss: Toward the Ideal Treatment for Obesity in the Twenty-First Century
Hope, D. C. D., Tan, T., & Bloom, S. R. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00442 · Cited by 35
“In a double-blind placebo-controlled study over 4 months, patients lost approximately 3 kg on average (48).”
BackgroundRoth, J. D., Hughes, H., Coffey, T. S., Maier, H., Trevaskis, J. L., & Anderson, C. M. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00395.2007 · Cited by 30
Antidiabetic medications and weight gain: Implications for the practicing physician
McFarlane, S. I. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0040-7 · Cited by 30
“Amylin analogues such as pramlintide have also been shown to reduce body weight in obese patients [ 42 ] and in diabetes patients treated with insulin [43].”
BackgroundAmylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity
Volčanšek, Š., Koceva, A., Jensterle, M., Janež, A., & Muzurović, E. M. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01733-8 · Cited by 35
“…use in conjunction with lifestyle intervention over a study period of 12 months resulted in placebo-corrected weight loss of up to 7.9% or 6.1 ± 2.1 kg when the participants received a dose of 120 mcg 3 times a day (t.i.d.) and of 7.2 ± 2.3 kg when the dose was 360 mcg 2 times a day (b.i.d.) [102].”
InfluentialKuhre, R. E., Ballarín-González, B., Brand, C. L., Glendorf, T., Madsen, K. G., Hjøllund, K. R., Hogendorf, W. F. J., Ipsen, D. H., Lundh, S. H., Kruse, T., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105862 · Cited by 28
“17,18 20–22 Simultaneous targeting of amylin and GLP-1 pathways with fixed-dose combination therapy of s.c. administered cagri-lintide 2.4 mg and the GLP-1RA semaglutide 2.4 mg (i.e., CagriSema), has shown greater reductions in weight loss compared with either agent alone, provided improvements in…”
InfluentialHarris, P. W. R., Kowalczyk, R., Hay, D. L., & Brimble, M. A. (2012) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-012-9325-9 · Cited by 26
“In a human clinical study, treatment with pramlintide resulted in sustained weight loss of *8–10 % after 1 year (Smith et al. 2008).”
Geisler, C. E., Décarie-Spain, L., Loh, M. K., Trumbauer, W., Gaisinsky, J., Klug, M. E., Pelletier, C., Davis, J. F., Schmidt, H. D., Roitman, M. F., et al. (2023) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.07.011 · Cited by 28
Evolving Approaches for Pharmacological Therapy of Obesity
Chao, A. M., Taylor, S. I., Moore, M., Amaro, A., & Wadden, T. A. (2024) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-031124-101146 · Cited by 30
What are the risks and the benefits of current and emerging weight-loss medications?
Robinson, J. R., & Niswender, K. D. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0058-x · Cited by 24
“In a 12-month placebo-controlled study of 146 individuals undergoing lifestyle intervention, 41% to 65% of pramlintide-treated subjects achieved at least a 5% weight loss compared with 18% of placebotreated patients [ 19 ].”
BackgroundResultInfluentialBriere, D. A., Qu, H., Lansu, K., He, M. M., Moyers, J. S., Coşkun, T., Long, A., Allen, D., O’Farrell, L. S., Bowen, B., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102271 · Cited by 25
“Pramlintide, a synthetic analog of human amylin approved for use in patients with diabetes, is an agonist that primarily activates amylin receptors over CTR. Early phase clinical trials of pramlintide demonstrated weight loss in people with obesity [18,19].”
Trevaskis, J. L., Wittmer, C., Athanacio, J., Griffin, P. S., Parkes, D. G., & Roth, J. D. (2016) · Obesity Science & Practice · doi:10.1002/osp4.62 · Cited by 26
“In humans with obesity, the synthetic amylin analogue pramlintide inhibited food intake and induced significant weight loss (9,10).”
Roth, J. D., D’Souza, L. J., Griffin, P. S., Athanacio, J., Trevaskis, J. L., Nazarbaghi, R., Jodka, C. M., Athanacio, J., Hoyt, J., Forood, B., et al. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01570.x · Cited by 21
“In diet-induced obese (DIO) rats and overweight/obese humans, the weight-lowering effects of amylin agonism have been repeatedly showed, and mechanistic studies in rodents suggest that body weight is reduced in a fat-specific, lean mass-preserving manner [1–3].”
BackgroundScott, R., Tan, T., & Bloom, S. R. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-407766-9.00007-9 · Cited by 20
“control, pramlintide has been shown to achieve and maintain weight loss (Smith et al., 2008); however, as with the GLP-1 analogues, pramlintide is not licensed for therapy of obesity without diabetes.”
BackgroundFeigh, M., Andreassen, K. V., Hjuler, S. T., Nielsen, R. H., Christiansen, C., Henriksen, K., & Karsdal, M. A. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31827c58ab · Cited by 22
“Thus, by influencing energy balance and regulation of body weight, amylin analogs hold promise as antiobesity therapy in clinical settings.(16,17,37) Recently, amylin treatment was also demonstrated to induce weight loss in estradiol-deficient and DIO rats,(18) thus introducing amylin agonism as a pharmacological inte…”
BackgroundG Protein-Coupled Receptors as Regulators of Energy Homeostasis
Tao, Y., Yuan, Z., & Xie, J. (2013) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-386933-3.00001-7 · Cited by 21
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 22
Antiobesity drug therapy: An individualized and comprehensive approach
Mauer, Y., Parker, M., & Kashyap, S. R. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.20080 · Cited by 26
Igel, L. I., Powell, A. G., Apovian, C. M., & Aronne, L. J. (2011) · Current Atherosclerosis Reports · doi:10.1007/s11883-011-0221-0 · Cited by 22
“[42].”
Self-citationWeight gain associated with antidiabetic medications
Provilus, A., Abdallah, M., & McFarlane, S. I. (2011) · Therapy · doi:10.2217/thy.11.8 · Cited by 27
Progressos recentes e novas perspectivas em farmacoterapia da obesidade
Faria, A. M., Mancini, M. C., de Melo, M. E., Cercato, C., & Halpern, A. (2010) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302010000600003 · Cited by 30
Safety, tolerability and pharmacokinetic characterisation of DACRA KBP‐042 in healthy male subjects
Henriksen, K., Broekhuizen, K., de Boon, W. M. I., Karsdal, M. A., Bihlet, A. R., Christiansen, C., Dillingh, M. R., de Kam, M., Kumar, R., Burggraaf, J., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14921 · Cited by 18
Dutta, D., Nagendra, L., Harish, B., Sharma, M., Joshi, A. S., Hathur, B., & Kamrul-Hasan, A. B. M. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_45_24 · Cited by 23
“[5,6] .”
Treating obesity: is it all in the gut?
Davenport, R. J., & Wright, S. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.10.025 · Cited by 21
Foll, C. L., & Lutz, T. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190034 · Cited by 27
“…does not seem to result in a loss of amylin-responsiveness (42, 114, 174, 207); similarly, clinical studies also indicate that the repeated administration of the amylin analog pramlintide produced durable actions in patients (260), arguing against amylin receptor downregulation or desensitization.”
Melander, S. A., Katri, A., Karsdal, M. A., & Henriksen, K. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175397 · Cited by 16
Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure
Lutz, T. A. (2016) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2016.4 · Cited by 18
Weight-Loss Pharmacotherapy: A Brief Review
Huizinga, M. M. (2007) · Clinical Diabetes · doi:10.2337/diaclin.25.4.135 · Cited by 16
Metadata
- Authors
- Smith, S. R., Aronne, L. J., Burns, C. M., Kesty, N. C., Halseth, A. E., & Weyer, C.
- Affiliations
- Pennington Biomedical Research Center, Louisiana State University, Baton Rouge, Louisiana
- Weill Cornell Medicine (US)
- Amylin Pharmaceuticals, San Diego, California
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2008-09-01
- Volume
- 31
- Issue
- 9
- Pages
- 1816-1823
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC2518351
- OpenAlex
- W2170571946
- Cited by
- 172
- References
- 19
- Citations by year
- 2026: 11 · 2025: 17 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 15 · 2020: 6 · 2019: 4 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 6 · 2014: 3 · 2013: 11 · 2012: 16
- FWCI
- 10.78
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- European Foundation for the Study of Diabetes
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- pramlintide, obesity, weight loss, lifestyle intervention, GLP-1 receptor agonists, dose-ranging, weight maintenance, nausea, adverse events, long-term efficacy, weight regain
- MeSH terms
- Adult, Amyloid, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Life Style, Male, Middle Aged, Placebos, Time Factors, Weight Loss, Body Mass Index, Single-Blind Method, Body Size, Islet Amyloid Polypeptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.